Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal
adenocarcinoma (PDAC) is the most common type of pancreatic cancer. In the past decade …

Abstract Background Pancreatic adenocarcinomas (PAs) have very poor prognoses even
when surgery is possible. Currently, there are no tissular biomarkers to predict long-term …

Background Although significant advances have been made recently to characterize the
biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by high heterogeneity, and the
postoperative prognosis of different patients often varies greatly. Therefore, the classification …

Simple Summary A highly desirable approach to diagnose a human disease quickly and
easily is to identify a chemical, protein, or antibody in a biofluid like blood or urine that is …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but …

Background Early detection of pancreatic ductal adenocarcinoma (PDAC) may improve the
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …

Metabolomics is an emerging scientific field focusing on compounds, also known as
metabolomes that are produced by biologic systems. Metabolomes represent phenotypic …

Simple Summary Pancreatic cancer is a clinically heterogeneous disease, and treatment
leads to different outcomes for people with similar diagnoses. Identifying patients who may …